COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD), a bio-pharmaceutical company, today announced a significant financing, management and board changes, and important steps toward successful commercialization of its core product Oxycyte™, a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
